Compare WING & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WING | BLTE |
|---|---|---|
| Founded | 1994 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 6.5B |
| IPO Year | 2015 | 2021 |
| Metric | WING | BLTE |
|---|---|---|
| Price | $154.93 | $151.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 28 | 8 |
| Target Price | ★ $336.00 | $181.14 |
| AVG Volume (30 Days) | ★ 968.4K | 162.4K |
| Earning Date | 04-29-2026 | 03-02-2026 |
| Dividend Yield | ★ 0.77% | N/A |
| EPS Growth | ★ 67.84 | N/A |
| EPS | ★ 6.21 | N/A |
| Revenue | ★ $696,853,000.00 | N/A |
| Revenue This Year | $18.23 | N/A |
| Revenue Next Year | $16.29 | $363.39 |
| P/E Ratio | $25.07 | ★ N/A |
| Revenue Growth | ★ 11.35 | N/A |
| 52 Week Low | $155.44 | $49.00 |
| 52 Week High | $388.14 | $200.00 |
| Indicator | WING | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 23.56 | 37.59 |
| Support Level | N/A | $148.78 |
| Resistance Level | $267.86 | $161.28 |
| Average True Range (ATR) | 10.44 | 7.34 |
| MACD | -3.91 | -1.84 |
| Stochastic Oscillator | 3.36 | 18.52 |
Founded in 1994 in Garland, Texas, Wingstop is a restaurant operator specializing in indulgent bone-in and boneless chicken wings, chicken tenders, fries, and, recently, chicken sandwiches. The firm's footprint has grown quickly since its inception, expanding to 2,932 global stores at the end of the third quarter of 2025. With a 98% franchised model, Wingstop generates the lion's share of its revenue from franchise royalties and advertising fees, with the remainder derived from a small footprint of company-owned stores.
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.